IRON
MCID: IRN002
MIFTS: 58

Iron Metabolism Disease (IRON)

Categories: Blood diseases, Metabolic diseases, Respiratory diseases

Aliases & Classifications for Iron Metabolism Disease

MalaCards integrated aliases for Iron Metabolism Disease:

Name: Iron Metabolism Disease 12 15
Iron Deficiency 75 55 72 33
Iron Metabolism Disorders 44 72
Iron Disorder 12 55
Disorder of Iron Metabolism 12
Iron 43

Classifications:



External Ids:

Disease Ontology 12 DOID:2351
ICD9CM 35 275.0
MeSH 44 D019189
SNOMED-CT 68 30913008
UMLS 72 C0012715 C0240066

Summaries for Iron Metabolism Disease

MedlinePlus : 43 Iron is a mineral that our bodies need for many functions. For example, iron is part of hemoglobin, a protein which carries oxygen from our lungs throughout our bodies. It helps our muscles store and use oxygen. Iron is also part of many other proteins and enzymes. Your body needs the right amount of iron. If you have too little iron, you may develop iron deficiency anemia. Causes of low iron levels include blood loss, poor diet, or an inability to absorb enough iron from foods. People at higher risk of having too little iron are young children and women who are pregnant or have periods. Too much iron can damage your body. Taking too many iron supplements can cause iron poisoning. Some people have an inherited disease called hemochromatosis. It causes too much iron to build up in the body. Centers for Disease Control and Prevention

MalaCards based summary : Iron Metabolism Disease, also known as iron deficiency, is related to hemochromatosis, type 3 and hemochromatosis, type 4. An important gene associated with Iron Metabolism Disease is HFE (Homeostatic Iron Regulator), and among its related pathways/superpathways are Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds and Insulin receptor recycling. The drugs Rivaroxaban and Edoxaban have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and liver, and related phenotypes are hematopoietic system and homeostasis/metabolism

Wikipedia : 75 Iron deficiency, or sideropaenia, is the state in which a body lacks enough iron to supply its needs.... more...

Related Diseases for Iron Metabolism Disease

Diseases related to Iron Metabolism Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1964)
# Related Disease Score Top Affiliating Genes
1 hemochromatosis, type 3 31.8 TFR2 SLC40A1 HJV HFE
2 hemochromatosis, type 4 31.5 TFR2 TF SLC40A1 HJV HFE
3 hemoglobinopathy 30.8 TF HFE EPO
4 vitamin b12 deficiency 30.8 TF EPO
5 iron overload in africa 30.4 TFRC TFR2 TF SLC40A1 HFE
6 iron-refractory iron deficiency anemia 30.4 HJV EPO
7 hypochromic microcytic anemia 30.2 TF SLC11A2 CP
8 porphyria cutanea tarda 30.2 TFRC TF HFE
9 nutritional deficiency disease 30.0 TF EPO CP
10 acquired polycythemia 29.9 TF EPO
11 beta-thalassemia 29.9 TFRC TFR2 TF HFE EPO
12 hemochromatosis type 2 29.8 TFR2 TF SLC40A1 HJV HFE
13 atransferrinemia 29.8 TFRC TFR2 TF SLC40A1 SLC11A2 HJV
14 hemoglobin h disease 29.8 TFRC TF EPO
15 pure red-cell aplasia 29.8 TF EPO
16 hyperferritinemia with or without cataract 29.7 TF HFE FTL
17 myelodysplastic syndrome 29.7 TFRC TF HFE EPO
18 angiomatous meningioma 29.7 TFRC TF
19 siderosis 29.6 TFRC TF SLC40A1 HFE
20 aceruloplasminemia 29.6 TFR2 TF HJV HFE FTL CP
21 ancylostomiasis 29.5 TF CP
22 folic acid deficiency anemia 29.5 TFRC TF EPO
23 analbuminemia 29.5 TF EPO
24 thalassemia 29.5 TFRC TF HFE EPO
25 protein-energy malnutrition 29.4 TF CP
26 eales disease 29.3 TF CP
27 wilson disease 29.2 TF HFE CP
28 inherited metabolic disorder 29.2 TFR2 TF HJV HFE
29 microcytic anemia 29.0 TFRC TF SLC11A2 IREB2 EPO
30 liver disease 28.9 TF HFE CP
31 hemosiderosis 28.7 TFRC TF SLC40A1 SLC11A2 HFE FTL
32 iron deficiency anemia 27.8 TFRC TFR2 TF SLC40A1 SLC11A2 HJV
33 hemochromatosis, type 1 27.7 TFRC TFR2 TF SLC40A1 SLC11A2 IREB2
34 deficiency anemia 26.3 TFRC TFR2 TF SLC40A1 SLC11A2 HJV
35 neurodegeneration with brain iron accumulation 1 12.7
36 neurodegeneration with brain iron accumulation 5 12.7
37 hypochromic microcytic anemia with iron overload 12.6
38 neurodegeneration with brain iron accumulation 4 12.6
39 neurodegeneration with brain iron accumulation 6 12.6
40 neurodegeneration with brain iron accumulation 3 12.6
41 neurodegeneration with brain iron accumulation 2b 12.6
42 neurodegeneration with brain iron accumulation 2a 12.6
43 disorder of iron metabolism and transport 12.6
44 neurodegeneration with brain iron accumulation 7 12.5
45 neurodegeneration with brain iron accumulation 8 12.5
46 anemia, hypochromic microcytic, with iron overload 2 12.5
47 myopathy with deficiency of iron-sulfur cluster assembly enzyme 12.3
48 gracile syndrome 12.2
49 genetic hyperferritinemia without iron overload 12.2
50 mitochondrial membrane protein-associated neurodegeneration 12.2

Comorbidity relations with Iron Metabolism Disease via Phenotypic Disease Network (PDN):


Deficiency Anemia Pulmonary Hemosiderosis

Graphical network of the top 20 diseases related to Iron Metabolism Disease:



Diseases related to Iron Metabolism Disease

Symptoms & Phenotypes for Iron Metabolism Disease

MGI Mouse Phenotypes related to Iron Metabolism Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.02 CP EPO HFE HJV IREB2 SLC11A2
2 homeostasis/metabolism MP:0005376 10 CP CYBRD1 EPO HFE HJV IREB2
3 cardiovascular system MP:0005385 9.97 CP CYBRD1 EPO HJV IREB2 SLC11A2
4 immune system MP:0005387 9.81 CP EPO HFE HJV IREB2 SLC11A2
5 integument MP:0010771 9.43 EPO HJV IREB2 SLC11A2 SLC40A1 TFRC
6 liver/biliary system MP:0005370 9.32 CP CYBRD1 EPO HFE HJV IREB2

Drugs & Therapeutics for Iron Metabolism Disease

Drugs for Iron Metabolism Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 657)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rivaroxaban Approved Phase 4 366789-02-8
2
Edoxaban Approved Phase 4 480449-70-5
3
Apixaban Approved Phase 4 503612-47-3 10182969
4
Vancomycin Approved Phase 4 1404-90-6 441141 14969
5
Nevirapine Approved Phase 4 129618-40-2 4463
6
Lumefantrine Approved Phase 4 82186-77-4 6437380
7
Rifampicin Approved Phase 4 13292-46-1 5381226 5458213
8
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
9
Artemether Approved Phase 4 71963-77-4 68911 119380
10
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
11
Halofantrine Approved Phase 4 69756-53-2 37393
12
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
13
Albendazole Approved, Vet_approved Phase 4 54965-21-8 2082
14
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
15
Topiramate Approved Phase 4 97240-79-4 5284627
16
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
17
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
18
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
19
Ribavirin Approved Phase 4 36791-04-5 37542
20
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605
21
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
22
Atorvastatin Approved Phase 4 134523-00-5 60823
23
Ledipasvir Approved Phase 4 1256388-51-8 67505836
24
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 67683363
25
Pravastatin Approved Phase 4 81093-37-0 54687
26
lanreotide Approved Phase 4 108736-35-2
27
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
28
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
29
Metformin Approved Phase 4 657-24-9 4091 14219
30
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
31
Zinc Approved, Investigational Phase 4 7440-66-6 32051
32
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
33
Iodine Approved, Investigational Phase 4 7553-56-2 807
34
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
35
Copper Approved, Investigational Phase 4 7440-50-8 27099
36
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
37
Darbepoetin alfa Approved, Investigational Phase 4 11096-26-7, 209810-58-2
38
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
39
Rifaximin Approved, Investigational Phase 4 80621-81-4 46783403 6436173
40
Choline Approved, Nutraceutical Phase 4 62-49-7 305
41
Taurine Approved, Nutraceutical Phase 4 107-35-7 1123
42
Ornithine Approved, Nutraceutical Phase 4 70-26-8, 3184-13-2 6262
43
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
44
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 54670067 5785
45
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
46
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
47
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 4 83-88-5 493570
48
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
49
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 59-43-8, 70-16-6 1130
50
Dihydroartemisinin Experimental, Investigational Phase 4 71939-50-9 6918483

Interventional clinical trials:

(show top 50) (show all 2176)
# Name Status NCT ID Phase Drugs
1 The Effect of a Nutrient Fortified Oat Drink on Iron, Zinc, Vitamin A, and Vitamin C Status Among Filipino Children Unknown status NCT01418898 Phase 4
2 Randomized, Controlled Study of Iron Supplementation of Infants With Birth Weights 2000-2500 g Unknown status NCT00558454 Phase 4 Iron
3 Randomized, Parallel Group, Clinical Trial Comparing Intravenous Iron Sucrose Versus Oral Ferrous Sulphate in the Treatment of Perioperative Iron Deficiency in Patients With Colo-Rectal Neoplasm and Iron Deficiency Anemia. Unknown status NCT00199277 Phase 4 i.v. iron sucrose;Oral iron
4 Effectiveness of Iron Supplementation in the Second Year of Life for Prevention of Iron Deficiency Unknown status NCT00479102 Phase 4 Ferripel-3 - iron polysaccharide complex for prevention
5 Treatment of Anemia in the 2nd Year of Life. Comparison of the Efficacy of Two Different Iron Preparations. Unknown status NCT00248716 Phase 4 Ferrous gluconate and iron polysaccharide complex
6 Effect of Intravenous Iron (Ferinject®) on Exercise Capacity and Quality of Life of Stable COPD Patients Unknown status NCT02416778 Phase 4 Ferric carboxymaltose, Ferinject® 50mg Iron/ml Solution for Injection / Infusion
7 Intravenous Iron Treatment In Iron Deficient Patients With Idiopathic Pulmonary Arterial Hypertension Unknown status NCT01288651 Phase 4 Ferricarboxymaltose
8 Effektivität Der in Der Schwangerschaftsvorsorge routinemässig Angewandten Eisenprophylaxe Unknown status NCT02487719 Phase 4 Iron sulfate and Iron polymaltose for prevention of iron deficiency anemia
9 Effect Of Intravenous Iron Versus Placebo On Muscle Oxidative Capacity And Physical Performance In Non Anemic Premenopausal Women With Low Ferritin Levels Unknown status NCT01374776 Phase 4 Double blind, randomized, placebo controlled inter
10 Multicenter Randomized Open-label Controlled Study to Investigate Treatment Response of IV Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia Secondary to Inflammatory Bowel Disease or Gastric Bypass Unknown status NCT02086968 Phase 4 Injectafer;Ferrous Sulfate tablets
11 Randomized Cross-Over Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With Inflammatory Bowel Disease Unknown status NCT02774057 Phase 4 Captafer®;Iron Sulfate
12 Iron Absorption Trial Unknown status NCT02228902 Phase 4 Ferrous fumarate;Ferrous gluconate
13 Effect of Iron Supplementation on Psychomotor Development of Non-anemic Exclusively or Predominantly Breastfed Infants: Randomized, Double-blind, Placebo-controlled Trial. Unknown status NCT02242188 Phase 4 Iron
14 The Impact of Treatment of Anaemia With Intravenous Iron on Haematological Values for Patients After Colorectal Surgery Unknown status NCT02999217 Phase 4 Iron isomaltoside;Saline
15 Supplementation With Lactoferrin in Preterm Newborns Unknown status NCT01172236 Phase 4 Lactoferrin;Lactoferrin
16 Effects of Early Short-term Intravenous Iron Supplements Combinded EPO in Preterm Infants Unknown status NCT02060851 Phase 4 Iron sucrose;EPO
17 Efficacy and Safety of Intravenous Iron Sucrose in Patients With Hip Fracture to Prevent Perioperative Anemia Unknown status NCT01084122 Phase 4 Iron sucrose
18 A Multi-Center, Open-Label, Randomized, Parallel Group Study of the Efficacy and Safety of Ferrlecit in the Maintenance of Iron Stores and Serum Hemoglobin Concentration in Hemodialysis Patients Receiving Erythropoietin. Unknown status NCT00223938 Phase 4 Oral Iron;sodium ferric gluconate;sodium ferric gluconate
19 The Value of Iron Treatment for Postoperative Patients With Anemia: a Randomized Double Blind Controlled Trial Unknown status NCT01975272 Phase 4 Ferinject;Ferrous fumarate;Placebo for ferrous fumarate;Placebo for ferinject
20 Open Randomized Phase IV Study on Intravenous Iron in Anemic Patients With Chronic Kidney Disease Unknown status NCT00204256 Phase 4 Iron sucrose
21 Predictors of Response to Treatment With Iron and Erythropoietin in Dialysis Anaemia Unknown status NCT02707757 Phase 4 Iron sucrose;Erythopoietin stimulating agent
22 A Randomized, Placebo Controlled, Double Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance Unknown status NCT00103753 Phase 4 deferiprone
23 Evaluation of the Efficacy in Decreasing Iron Absorption in Patients With Congenital Dyserythropoietic Anemia Type I by Treatment With LOSEC Unknown status NCT01795794 Phase 4 omeprazole
24 An Pilot Study to Assess the Efficacy of Intravenous Iron Isomaltoside 1000 (Monofer®) in the Management of Anaemia Associated With the Palliative Management of Oesophagogastric Adenocarcinoma Unknown status NCT01927328 Phase 4 Iron isomaltoside 1000
25 Does Intraoperative Intravenous Iron Sucrose Enhance Postoperative Oxygenation Profile in Total Arthroplasty Surgery? Unknown status NCT02544828 Phase 4 Iron Sucrose 200mg;placebo
26 Anemia Treatment in Inflammatory Bowel Disease: Predictive Factors of Response to Oral Iron Treatment Unknown status NCT02760940 Phase 4 oral liposomal iron
27 A Comparison Between Two Different Oral Appliance Therapies: Somnodent vs Herbst Appliance in Patients With Mild and Moderate OSA Unknown status NCT02724865 Phase 4
28 The Effect of Ferric Citrate on Inflammation and Lipid Levels in Patients on Hemodialysis Unknown status NCT02661295 Phase 4 Ferric Citrate
29 The Effect of Intra Venus Ferric Carboxymaltose Preoperative on Hemoglobin and Blood Transfusion Post Cardiac Surgery Unknown status NCT02939794 Phase 4 Ferinject;Placebo
30 Efficacy and Safety of Non-vitamin K Oral Anticoagulants and Vitamin K Oral Anticoagulants on Some Metabolic and Coagulation Parameters in Diabetic and Nondiabetic Patients With First Diagnosis of Non-valvular Atrial Fibrillation Unknown status NCT02935855 Phase 4 Dabigatran;Apixaban;Rivaroxaban;Edoxaban;Warfarin;Acenocumarole
31 Efficacy and Safety of Erythropoietin in the Treatment of Anemia in Patients With Lymphoma After Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT03010579 Phase 4 erythropoietin;iron supplementation
32 Sienna+® Injection Time Study: A Prospective Multicentre, Controlled Clinical Trial to Evaluate the Performance of Superparamagnetic Iron Oxide vs. Standard Technique as Tracer in Sentinel Node Biopsy Unknown status NCT02612870 Phase 4
33 An Open-labeled Pilot Study to Determine the Efficacy of an E2//Nomegestrol Acetate (E2/NOMAC)Combination Oral Contraceptive (COC) in the Management of Heavy Menstrual Bleeding (HMB) Unknown status NCT01715025 Phase 4 E2Nomac
34 Non-Invasive Positive Pressure Mask Ventilation vs Extrathoracic Biphasic Cuirass Ventilation in Patients With Acute Respiratory Failure: A Randomized Prospective Study. Unknown status NCT00331656 Phase 4
35 Randomized Double Blind Controlled Trial for the Treatment of Nucleic Acid Amplification Test (NAAT)+/Toxin Enzyme Immunoassay (EIA)- Clostridium Difficile in the Hematology Oncology Population Unknown status NCT03030248 Phase 4 Vancomycin Oral Capsule;Placebo Oral Capsule
36 Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease Unknown status NCT01038050 Phase 4 Ginkgo Biloba Extract (GBE)
37 Pharmacokinetic Interaction Between Coartem® and Either Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients Unknown status NCT00620438 Phase 4 Lumefantrine-artemether and nevirapine;lumefantrine-artemether and efavirenz;Lumefantrine-artemether and rifampicin
38 Assessment of the Effects of the Combination of Spironolactone to Conventional Pharmacotherapy in Dialysis Patients Unknown status NCT01128101 Phase 4 Spironolactone
39 Efficacy and Safety of Artemether + Lumefantrine and Dihydroartemisinin + Piperaquine for the Treatment of Uncomplicated Malaria in Guinea-Bissau. Unknown status NCT01704508 Phase 4 Artemether-lumefantrine;Dihydroartemisinin-piperaquine
40 Prevention of Iron Deficiency in Breastfed Infants Completed NCT01444261 Phase 4
41 The Effect of Lactoferrin Versus Iron Supplement in Treating Iron Deficiency Anemia and Helping Weight Loss in Obese School Age Children Completed NCT04014855 Phase 4 Iron Supplement
42 Dialysis Patients' Response to IV Iron With Elevated Ferritin Completed NCT00224081 Phase 4 Sodium ferric gluconate,
43 Randomized Double-Blind Parallel Group MultiCenter Study of the Efficacy of Two Doses of Ferrlecit® in Treatment of Iron Deficiency in Pediatric Hemodialysis Patients Receiving Epoetin. Completed NCT00223964 Phase 4 Ferrlecit (sodium ferric gluconate complex in sucrose injection)
44 A Randomised, Double-blind Controlled Phase 4 Study to Compare the Efficacy and Safety of Intravenous Ferric Carboxymaltose With Placebo in Patients With Chronic Heart Failure and Iron Deficiency Completed NCT01453608 Phase 4 Ferinject (ferric carboxymaltose);Placebo (saline)
45 A Prospective, Randomized, Multi-centered Trial to Compare the Efficacy and Safety of Intravenous Iron Sucrose (Venoferrum®) With Oral Iron Acetyl-transferrin Hydroglycerin (Bolgre®) in Pregnant Women With Iron Deficiency Anemia Completed NCT00802139 Phase 4 venoferrum(iron sucrose);Bolgre (Iron acetyl-transferase)
46 A Randomized, Controlled, Open-label Study of the Safety and Efficacy of Ferrlecit® vs Oral Iron in Iron Deficient Patients With Chronic Kidney Disease Completed NCT00224055 Phase 4 Sodium Ferric Gluconate Complex in Sucrose Injection;Ferrous sulfate tablets
47 A Randomized, Controlled, Open-label Study of the Safety and Efficacy of Ferrlecit® vs Oral Iron in Iron Deficient Patients With Chronic Kidney Disease Being Treated With Erythropoietic Therapy Completed NCT00224042 Phase 4 Sodium Ferric Gluconate complex in sucrose;Ferrous sulfate tablets
48 Use of FERAHEME® (Ferumoxytol) for Severe Chronic Kidney Disease and Peritoneal Dialysis Completed NCT01942460 Phase 4 Ferumoxytol
49 Ferumoxytol for Anemia of CKD Trial (FACT): A Phase IV, Open-Label, Multicenter Trial, With MRI Substudy, of Repeated Doses of Ferumoxytol Compared With Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA) in Chronic Kidney Disease (CKD) Patients on Hemodialysis Completed NCT01227616 Phase 4 Ferumoxytol;Iron Sucrose
50 Endovenous Versus Liposomal Iron in CKD Completed NCT01864161 Phase 4 gluconate iron;Liposomal iron

Search NIH Clinical Center for Iron Metabolism Disease

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Ferric pyrophosphate citrate
Iron
Iron Dextran

Cochrane evidence based reviews: iron metabolism disorders

Genetic Tests for Iron Metabolism Disease

Anatomical Context for Iron Metabolism Disease

MalaCards organs/tissues related to Iron Metabolism Disease:

41
Kidney, Heart, Liver, Testes, Brain, Bone, Breast

Publications for Iron Metabolism Disease

Articles related to Iron Metabolism Disease:

(show top 50) (show all 18751)
# Title Authors PMID Year
1
Iron status and risk factors of iron deficiency among pregnant women in Singapore: a cross-sectional study. 38 17
30975203 2019
2
Duplicate portion sampling gives the most accurate iron intake estimate: Implications for iron status of female students. 38 17
30982441 2018
3
Multiple-micronutrient supplementation for women during pregnancy. 17
30873598 2019
4
Elevated soluble transferrin receptor levels reflect increased erythropoietic drive rather than iron deficiency in pediatric sickle cell disease. 9 38
20486179 2010
5
Alpha 1-acid glycoprotein, hepcidin, C-reactive protein, and serum ferritin are correlated in anemic schoolchildren with Schistosoma haematobium. 9 38
20410090 2010
6
Posttransplant anemia in solid organ recipients. 9 38
20303457 2010
7
Usefulness of measuring reticulocyte hemoglobin equivalent in the management of haemodialysis patients with iron deficiency. 9 38
19624802 2010
8
Ceramide in suicidal death of erythrocytes. 9 38
20502001 2010
9
[Soluble tranferrin receptor in the biological diagnosis of iron deficiency. Report of 24 cases]. 9 38
20209848 2009
10
Iron stores, periodic leg movements, and sleepiness in obstructive sleep apnea. 9 38
20465018 2009
11
Ferric carboxymaltose in patients with heart failure and iron deficiency. 9 38
19920054 2009
12
The role of transferrin receptor 1 and 2 in transferrin-bound iron uptake in human hepatoma cells. 9 38
19828835 2009
13
Impact of socioeconomic and health related factors on the iron status of adolescent girls from two boarding schools in Southern Benin. 9 38
20306766 2009
14
[Treatment anaemia of chronic kidney disease in predialysis patients (stage 1-4)]. 9 38
20232547 2009
15
Transferrin and ferritin response to bacterial infection: the role of the liver and brain in fish. 9 38
19428486 2009
16
Differential ferritin expression is associated with iron deficiency in coeliac disease. 9 38
19404207 2009
17
Influence of inflammation as measured by alpha-1-acid glycoprotein on iron status indicators among HIV-positive postpartum Zimbabwean women. 9 38
18506200 2009
18
Pediatric reference intervals for soluble transferrin receptor and transferrin receptor-ferritin index. 9 38
19718534 2009
19
Abnormal brain iron homeostasis in human and animal prion disorders. 9 38
19283067 2009
20
Evaluation of iron deficiency as a nutritional adaptation to infectious disease: an evolutionary medicine perspective. 9 38
18949769 2009
21
Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency. 9 38
19147412 2009
22
Early effects on T lymphocyte response to iron deficiency in mice. Short communication. 9 38
18825318 2009
23
Differing expression of genes involved in non-transferrin iron transport across plasma membrane in various cell types under iron deficiency and excess. 9 38
18830567 2009
24
The soluble transferrin receptor (TfR)-F-Index is not applicable as a test for iron status in patients with chronic lymphocytic leukemia. 9 38
19743956 2009
25
Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. 9 38
18815282 2009
26
Suicide for survival--death of infected erythrocytes as a host mechanism to survive malaria. 9 38
19710527 2009
27
Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. 9 38
18987297 2009
28
[Immune, inflammatory, and nutritional protein profile in children with iron deficiency in Côte d'Ivoire]. 9 38
19801348 2009
29
Parenteral ascorbic acid in haemodialysis patients. 9 38
18827578 2008
30
Effect of intravenous ascorbic acid in hemodialysis patients with anemia and hyperferritinemia. 9 38
18974579 2008
31
Erythrocyte programmed cell death. 9 38
18720418 2008
32
[Old and new iron parameters in iron metabolism and diagnostics]. 9 38
18791966 2008
33
Facility factors dominate the ability to achieve target haemoglobin levels in haemodialysis patients. 9 38
18469314 2008
34
Economic evaluation in Sweden of epoetin beta with intravenous iron supplementation in anaemic patients with lymphoproliferative malignancies not receiving chemotherapy. 9 38
18613854 2008
35
Iron-independent phosphorylation of iron regulatory protein 2 regulates ferritin during the cell cycle. 9 38
18574241 2008
36
Soluble transferrin receptor and sTfR-F index for assessing concurrent iron deficiency in patients with chronic renal failure. 9 38
18317758 2008
37
Alteration of mRNA expression of molecules related to iron metabolism in adenine-induced renal failure rats: a possible mechanism of iron deficiency in chronic kidney disease patients on treatment. 9 38
18174266 2008
38
[Expression of iron regulatory protein-2 and ferritins in intestinal mucosa of rats with iron deficiency]. 9 38
18549630 2008
39
Reticulocyte haemoglobin content vs. soluble transferrin receptor and ferritin index in iron deficiency anaemia accompanied with inflammation. 9 38
18279424 2008
40
Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking. 9 38
18029550 2008
41
Bivariate mixture modeling of transferrin saturation and serum ferritin concentration in Asians, African Americans, Hispanics, and whites in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. 9 38
18201677 2008
42
Potential roles of erythropoietin in the management of anaemia and other complications diabetes. 9 38
17645562 2008
43
Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure. 9 38
18094727 2008
44
Effect of erythropoietin on hepcidin, DMT1 with IRE, and hephaestin gene expression in duodenum of rats. 9 38
18306987 2008
45
Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia. 9 38
18212498 2008
46
Prognostic value of reticulocyte hemoglobin content to diagnose iron deficiency in 6-24-month-old children. 9 38
18971604 2008
47
The relationship between iron deficiency anemia and lipid metabolism in premenopausal women. 9 38
18004086 2007
48
Molecular genetic studies of DMT1 on 12q in French-Canadian restless legs syndrome patients and families. 9 38
17510944 2007
49
Iron deficiency and NRAMP1 polymorphisms (INT4, D543N and 3'UTR) do not contribute to severity of anaemia in tuberculosis in the Indonesian population. 9 38
17466092 2007
50
Inflammation and iron deficiency in the hypoferremia of obesity. 9 38
17438557 2007

Variations for Iron Metabolism Disease

Expression for Iron Metabolism Disease

Search GEO for disease gene expression data for Iron Metabolism Disease.

Pathways for Iron Metabolism Disease

Pathways related to Iron Metabolism Disease according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.04 TFRC TF SLC40A1 SLC11A2 FTL CYBRD1
2
Show member pathways
12.15 TFRC TF SLC40A1 SLC11A2 FTL CYBRD1
3 11.67 TFRC TF EPO
4
Show member pathways
11.59 SLC40A1 SLC11A2 CP
5 11.44 TFRC TF EPO CP
6 11.38 TF SLC40A1 SLC11A2 FTL CYBRD1
7 11.18 TF EPO
8 11.03 TFRC TF SLC40A1 SLC11A2 FTL CP
9 11.01 SLC11A2 EPO
10 10.25 HJV HFE
11 10.18 TFRC TFR2 TF SLC40A1 SLC11A2 IREB2

GO Terms for Iron Metabolism Disease

Cellular components related to Iron Metabolism Disease according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.91 TFRC TFR2 SLC40A1 SLC11A2 HFE
2 extracellular space GO:0005615 9.91 TFRC TF HJV HFE EPO CP
3 perinuclear region of cytoplasm GO:0048471 9.78 TFRC TF SLC11A2 HFE
4 cytoplasmic vesicle GO:0031410 9.77 TFRC TFR2 TF SLC11A2 HFE
5 cell surface GO:0009986 9.72 TFRC TF SLC11A2 HJV EPO
6 endosome membrane GO:0010008 9.63 TFRC TF SLC11A2
7 blood microparticle GO:0072562 9.58 TFRC TF CP
8 early endosome GO:0005769 9.56 TFRC TF SLC11A2 HFE
9 clathrin-coated vesicle membrane GO:0030665 9.49 TFRC TF
10 recycling endosome GO:0055037 9.46 TFRC TF SLC11A2 HFE
11 basal part of cell GO:0045178 9.13 TF SLC11A2 HFE
12 HFE-transferrin receptor complex GO:1990712 9.02 TFRC TFR2 TF HJV HFE

Biological processes related to Iron Metabolism Disease according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 ion transport GO:0006811 9.85 TF SLC40A1 SLC11A2 HFE CP
2 iron ion transport GO:0006826 9.63 TFR2 TF SLC40A1 SLC11A2 IREB2 FTL
3 transferrin transport GO:0033572 9.62 TFRC TFR2 TF HFE
4 acute-phase response GO:0006953 9.61 TFR2 HFE EPO
5 multicellular organismal iron ion homeostasis GO:0060586 9.58 SLC40A1 SLC11A2 HFE
6 response to iron ion GO:0010039 9.56 TFR2 SLC11A2 HFE CYBRD1
7 cellular response to iron ion GO:0071281 9.54 TFR2 TF HFE
8 osteoclast differentiation GO:0030316 9.52 TFRC IREB2
9 positive regulation of receptor-mediated endocytosis GO:0048260 9.51 TF HFE
10 iron ion homeostasis GO:0055072 9.5 TFR2 TF SLC40A1 SLC11A2 HJV HFE
11 copper ion transport GO:0006825 9.49 SLC11A2 CP
12 positive regulation of peptide hormone secretion GO:0090277 9.48 TFR2 HFE
13 cellular iron ion homeostasis GO:0006879 9.36 TFRC TFR2 TF SLC40A1 SLC11A2 IREB2

Molecular functions related to Iron Metabolism Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ferrous iron binding GO:0008198 9.46 TF FTL
2 co-receptor binding GO:0039706 9.43 TFR2 HFE
3 ferric iron binding GO:0008199 9.4 TF FTL
4 ferroxidase activity GO:0004322 9.37 FTL CP
5 iron ion transmembrane transporter activity GO:0005381 9.32 SLC40A1 SLC11A2
6 ferrous iron transmembrane transporter activity GO:0015093 9.26 SLC40A1 SLC11A2
7 transferrin transmembrane transporter activity GO:0033570 9.16 TFRC TFR2
8 transferrin receptor activity GO:0004998 8.96 TFRC TFR2
9 transferrin receptor binding GO:1990459 8.8 TF HJV HFE
10 protein binding GO:0005515 10.22 TFRC TFR2 TF SLC40A1 SLC11A2 IREB2

Sources for Iron Metabolism Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....